Tolerability of high-dose topical tretinoin: the Veterans Affairs Topical Tretinoin Chemoprevention Trial

Geng, A.; Weinstock, Martin A.; Hall, Russell P.; Eilers, David; Naylor, Mark F.; Kalivas, James

doi:10.1111/j.1365-2133.2009.09341.x

Cited by 15 publications

(19 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Application of topical retinoids has been shown to induce a manifold increase of the epidermal concentration although no significant increase of plasma retinoids was observed (Arsić & Vuleta, 1999). Topical tretinoin is the most commonly used retinoid for acne (Geng et al, 2009). However, its topical application can lead to local irritation such as erythema, peeling and burning at the application site and increased susceptibility to sunlight (Elbaum, 1988;Brisaert et al, 2001).…”

Section: Introductionmentioning

confidence: 99%

Tretinoin-loaded liposomal formulations: from lab to comparative clinical study in acne patients

et al. 2015

View full text Add to dashboard Cite

Topical tretinoin is the most commonly used retinoid for acne. However, its irritative potential on the applied area and the barrier properties of the stratum corneum limit its use. The objective of the present study was to formulate tretinoin liposomal gel to obtain a formula with lower skin irritation potential and greater clinical effect. A statistical 2 4 factorial design was adopted. Sixteen formulae prepared and were properly evaluated. A candidate formula (F13G) prepared with 0.025% tretinoin, phospholipid-cholesterol-dicetylphosphate (9:1:0.01) and incorporated in 1% carbopol gel was selected for skin irritation test. Clinical study was conducted on acne patients and compared to marketed product. All liposomes formulations were spherical in shape. The addition of cholesterol in the film hydration method significantly decreased the vesicle size, and increased the percentage of incorporation efficiency at (p50.05). The presence of dicetylphosphate significantly increased drug release but did not affect the percentage of incorporation efficiency and vesicle size. The results of the clinical study in acne patients revealed that F13G showed significantly higher efficacy when compared to marketed product (p50.05).

show abstract

Section: Introductionmentioning

confidence: 99%

Tretinoin-loaded liposomal formulations: from lab to comparative clinical study in acne patients

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The methodology of the VATTC Trial (CSP #402) has been published (Weinstock et al, 2001(Weinstock et al, , 2009a(Weinstock et al, , b, 2012Christian et al, 2008;Criscione et al, 2009;Dore et al, 2009;Geng et al, 2009;Weinstock, 2010, 2011;Baibergenova and Weinstock, 2011;Nunes et al, 2011). The VATTC Trial included participants recruited from the VA Medical Centers in the following US cities: Chicago, IL; Durham, NC; Long Beach, CA; Miami, FL; Oklahoma City, OK; and Phoenix, AZ.…”

Section: Methodsmentioning

confidence: 99%

Predictors of Basal Cell Carcinoma in High-Risk Patients in the VATTC (VA Topical Tretinoin Chemoprevention) Trial

Dyer

Weinstock

Cohen

et al. 2012

Journal of Investigative Dermatology

View full text Add to dashboard Cite

Basal cell carcinoma (BCC) is the most common cancer in the United States today, and patients who have had one are likely to have multiple carcinomas over time. Predictors of new BCCs on the face and ears among those at very high risk have not been studied in detail. We sought to do so prospectively in the context of a 6-year trial. We found that the number of BCCs in the prior 5 years was the most important predictor. Age, sun sensitivity, occupational sun exposure before the age of 30 years (but not afterward), lower educational level, history of eczema, the use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and more sunscreen use in the week, but not the 6 months, before enrollment were also independent predictors, but sunburns, baseline sun exposure, and other sun-protective measures, other skin cancers, and actinic keratoses were not. None of the eczema patients had a history of topical calcineurin use. The cumulative risk of BCC was 55% at 5 years. These findings document the key risk factors in this very high-risk population, suggesting that the history of eczema may increase the risk in those at high risk and that early sun exposure is important even in this group, and underscoring the need for chemopreventive strategies.

show abstract

“…[116][117][118][119]123,[125][126][127][128][129][130][131][132][133][134][135][136][137][138][139][140][141] …”

Section: Follow-up and Reducing Risk For Future Skin Cancersunclassified

Guidelines of care for the management of basal cell carcinoma

Baum¹,

Bordeaux²,

Brown³

et al. 2018

Journal of the American Academy of Dermatology

326

219

View full text Add to dashboard Cite

Basal cell carcinoma (BCC) is the most common form of human cancer, with a continually increasing annual incidence in the United States. When diagnosed early, the majority of BCCs are readily treated with office-based therapy, which is highly curative. In these evidence-based guidelines of care, we provide recommendations for the management of patients with BCC, as well as an in-depth review of the best available literature in support of these recommendations. We discuss biopsy techniques for a clinically suspicious lesion and offer recommendations for the histopathologic interpretation of BCC. In the absence of a formal staging system, the best available stratification based on risk for recurrence is reviewed. With regard to treatment, we provide recommendations on treatment modalities along a broad therapeutic spectrum, ranging from topical agents and superficially destructive modalities to surgical techniques and systemic therapy. Finally, we review the available literature and provide recommendations on prevention and the most appropriate follow-up for patients in whom BCC has been diagnosed. ( J Am Acad Dermatol

show abstract

Tolerability of high-dose topical tretinoin: the Veterans Affairs Topical Tretinoin Chemoprevention Trial

Cited by 15 publications

References 35 publications

Tretinoin-loaded liposomal formulations: from lab to comparative clinical study in acne patients

Tretinoin-loaded liposomal formulations: from lab to comparative clinical study in acne patients

Predictors of Basal Cell Carcinoma in High-Risk Patients in the VATTC (VA Topical Tretinoin Chemoprevention) Trial

Guidelines of care for the management of basal cell carcinoma

Contact Info

Product

Resources

About